Asset profile
Retifanlimab
Monoclonal antibody
Evidence outlook
Approved: Merkel Cell Carcinoma, Squamous Cell Carcinoma of the Anal Canal
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
Also in development:Non-Small Cell Lung Cancer · Phase 3
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
84 competitors in this universe: 22 direct rivals (same mechanism and indication), 1 same-class, 61 same-indication.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Retifanlimab: this drug | Approved | Monoclonal antibody | PD-1 | ||
| Cemiplimab | Approved | Monoclonal antibody | PD-1 | ||
| Nivolumab | Approved | Monoclonal antibody | PD-1 | ||
| Opdivo Qvantig | Approved | Monoclonal antibody | PD-1 | ||
| Pembrolizumab | Approved | Monoclonal antibody | PD-1 | ||
| Pembrolizumab Berahyaluronidase Alfa | Approved | Monoclonal antibody | PD-1 | ||
| Toripalimab | Approved | Monoclonal antibody | PD-1 | ||
| Abp 234 | Phase 3 | Monoclonal antibody | PD-1 | ||
| Balstilimab | Phase 3 | Monoclonal antibody | PD-1 | ||
| Camrelizumab | Phase 3 | Monoclonal antibody | PD-1 | ||
| Cetrelimab | Phase 3 | Monoclonal antibody | PD-1 | ||
| CT-P51 | Phase 3 | Small molecule | PD-1 | ||
| Dostarlimab | Phase 3 | Monoclonal antibody | PD-1 | ||
| Enlonstobart | Phase 3 | Monoclonal antibody | PD-1 | ||
| MB12 | Phase 3 | Monoclonal antibody | PD-1 | ||
| Penpulimab | Phase 3 | Monoclonal antibody | PD-1 |
…and 69 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
16 further head-to-head pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
(26 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (3)
October 2026 (1)
What to watch
November 2026 (1)
What to watch
December 2026 (1)
What to watch
2027 (14)
January 2027 (3)
What to watch
What to watch
What to watch
March 2027 (1)
What to watch
April 2027 (1)
What to watch
June 2027 (3)
What to watch
What to watch
What to watch
September 2027 (1)
What to watch
October 2027 (1)
What to watch
December 2027 (4)
What to watch
What to watch
What to watch
What to watch
2028 (4)
January 2028 (1)
What to watch
March 2028 (1)
What to watch
August 2028 (1)
What to watch
December 2028 (1)
What to watch
2029 (3)
January 2029 (1)
What to watch
December 2029 (2)
What to watch
What to watch
2030 (1)
October 2030 (1)
What to watch
2031 (1)
May 2031 (1)
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.